This Article Full Text Full Text (PDF) Supplemental Data Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosenzweig, J. L. Articles by Kawamori, R. Search for Related Content PubMed PubMed Citation Articles by Rosenzweig, J. L. Articles by Kawamori, R. Related Collections Lipid Cardiovascular Endocrinology Diabetes and Insulin Metabolism Obesity

Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline

Boston Medical Center and Boston University School of Medicine (J.L.R.), Boston, Massachusetts 02118; University of Pisa School (E.F.), 56126 Pisa, Italy; University of Texas Southwestern Medical Center (S.M.G.), Dallas, Texas 75390; University of Texas Health Science Center (S.M.H.), San Antonio, Texas 78249; ¹Vrije Universiteit Medical Center (R.J.H.), 1081 Amsterdam, The Netherlands; Joslin Diabetes Center (E.S.H.), Boston, Massachusetts 02215; and Juntendo University School of Medicine (R.K.), 113-8421 Tokyo, Japan

Address all correspondence to: The Endocrine Society, 8401 Connecticut Avenue, Suite 900, Chevy Chase, Maryland 20815. E-mail: govt-prof{at}endo.society.org. Telephone: 301-941-0200. Address all reprint requests for orders of 101 and more to: Heather Edwards, Reprint Sales Specialist, Cadmus Professional Communications, Telephone: 410-691-6214, Fax: 410-684-2789 or by E-mail: endoreprints{at}cadmus.com. Address all reprint requests for orders of 100 or less to Society Services, Telephone: 301-941-0210 or by E-mail: societyservices{at}endo-society.org.

Objective: The objective was to develop clinical practice guidelines for the primary prevention of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) in patients at metabolic risk.

Conclusions: Healthcare providers should incorporate into their practice concrete measures to reduce the risk of developing CVD and T2DM. These include the regular screening and identification of patients at metabolic risk (at higher risk for both CVD and T2DM) with measurement of blood pressure, waist circumference, fasting lipid profile, and fasting glucose. All patients identified as having metabolic risk should undergo 10-yr global risk assessment for either CVD or coronary heart disease. This scoring will determine the targets of therapy for reduction of apolipoprotein B-containing lipoproteins. Careful attention should be given to the treatment of elevated blood pressure to the targets outlined in this guideline. The prothrombotic state associated with metabolic risk should be treated with lifestyle modification measures and in appropriate individuals with low-dose aspirin prophylaxis. Patients with prediabetes (impaired glucose tolerance or impaired fasting glucose) should be screened at 1- to 2-yr intervals for the development of diabetes with either measurement of fasting plasma glucose or a 2-h oral glucose tolerance test. For the prevention of CVD and T2DM, we recommend that priority be given to lifestyle management. This includes antiatherogenic dietary modification, a program of increased physical activity, and weight reduction. Efforts to promote lifestyle modification should be considered an important component of the medical management of patients to reduce the risk of both CVD and T2DM.

This article has been cited by other articles:

				K. Feigenbaum and L. Longstaff Management of the Metabolic Syndrome in Patients With Human Immunodeficiency Virus The Diabetes Educator, May 1, 2010; 36(3): 457 - 464. [Abstract] [Full Text] [PDF]

				R. A. Wild, E. Carmina, E. Diamanti-Kandarakis, A. Dokras, H. F. Escobar-Morreale, W. Futterweit, R. Lobo, R. J. Norman, E. Talbott, and D. A. Dumesic Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society J. Clin. Endocrinol. Metab., May 1, 2010; 95(5): 2038 - 2049. [Abstract] [Full Text] [PDF]

				I. N. Karatsoreos, S. M. Bhagat, N. P. Bowles, Z. M. Weil, D. W. Pfaff, and B. S. McEwen Endocrine and Physiological Changes in Response to Chronic Corticosterone: A Potential Model of the Metabolic Syndrome in Mouse Endocrinology, May 1, 2010; 151(5): 2117 - 2127. [Abstract] [Full Text] [PDF]

				H. A. Amundson, M. K. Butcher, D. Gohdes, T. O. Hall, T. S. Harwell, S. D. Helgerson, K. K. Vanderwood, and for the Montana Cardiovascular Disease and Diabete Translating the Diabetes Prevention Program Into Practice in the General Community: Findings From the Montana Cardiovascular Disease and Diabetes Prevention Program The Diabetes Educator, March 1, 2009; 35(2): 209 - 223. [Abstract] [Full Text] [PDF]

				A. Sniderman and A. Solhpour Targeting Targets for LDL-Lowering Therapy: Lessons from the Collaborative Atorvastatin Diabetes Study (CARDS) Clin. Chem., March 1, 2009; 55(3): 391 - 393. [Full Text] [PDF]

				A. D. Sniderman and C. D. Furberg Why Guideline-Making Requires Reform JAMA, January 28, 2009; 301(4): 429 - 431. [Full Text] [PDF]